Please assess the completion status of the following clinical trial:

Trial Title: Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ICD-10-CM diagnosis code of D68.32 (Hemorrhagic disorder due to extrinsic circulating anticoagulants) as part of an inpatient admission~* Taking either an oral FXa inhibitor or enoxaparin at the time of hospitalization for their bleeding event~* Treated with either andexanet alfa or 4F-PCC during the hospitalization for their bleeding event~* Had documented discharge disposition~Exclusion Criteria:~* Less than 18 years old~* Treated with both andexanet alfa and 4F-PCC during the hospitalization for their bleeding event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Patients hospitalized for an anticoagulation-related major bleed (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).